265 related articles for article (PubMed ID: 12132049)
21. Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival.
Sucak GT; Özkurt ZN; Suyani E; Yaşar DG; Akdemir ÖÜ; Aki Z; Yeğin ZA; Yağci M; Kapucu ÖL
Ann Hematol; 2011 Nov; 90(11):1329-36. PubMed ID: 21437590
[TBL] [Abstract][Full Text] [Related]
22. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM
J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443
[TBL] [Abstract][Full Text] [Related]
23. Tandem high-dose therapy followed by autologous stem-cell transplantation for refractory or relapsed high grade non-Hodgkin's lymphoma with poor prognosis factors: a prospective pilot study.
Le Gouill S; Moreau P; Morineau N; Harousseau JL; Milpied N
Haematologica; 2002 Mar; 87(3):333-4. PubMed ID: 11869953
[TBL] [Abstract][Full Text] [Related]
24. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
[TBL] [Abstract][Full Text] [Related]
25. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
26. Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients.
Ruiz-Soto R; Sergent G; Gisselbrecht C; Larghero J; Ertault M; Hennequin C; Manson J; de Kerviler E; Briere J; Mounier N
Cancer; 2005 Dec; 104(12):2735-42. PubMed ID: 16284986
[TBL] [Abstract][Full Text] [Related]
27. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease.
Gallamini A; Rigacci L; Merli F; Nassi L; Bosi A; Capodanno I; Luminari S; Vitolo U; Sancetta R; Iannitto E; Trentin L; Stelitano C; Tavera S; Biggi A; Castagnoli A; Versari A; Gregianin M; Pelosi E; Torchio P; Levis A
Haematologica; 2006 Apr; 91(4):475-81. PubMed ID: 16585014
[TBL] [Abstract][Full Text] [Related]
28. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
29. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
Arranz R; Conde E; Grande C; Mateos MV; Gandarillas M; Albo C; Lahuerta JJ; Fernández-Rañada JM; Hernández MT; Alonso N; García Vela JA; Garzón S; Rodríguez J; Caballero D;
Eur J Haematol; 2008 Mar; 80(3):227-35. PubMed ID: 18088400
[TBL] [Abstract][Full Text] [Related]
30. Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation.
Kahl C; Leithäuser M; Wolff D; Steiner B; Hartung G; Casper J; Freund M
Ann Hematol; 2002 Nov; 81(11):646-50. PubMed ID: 12454703
[TBL] [Abstract][Full Text] [Related]
31. Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma.
Moser EC; Kluin-Nelemans HC; Carde P; Meerwaldt JH; Tirelli U; Aleman BM; Baars J; Thomas J; van Glabbeke M; Noordijk EM
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1168-77. PubMed ID: 16887289
[TBL] [Abstract][Full Text] [Related]
32. [High dose chemoradiotherapy with autologous hemotopoietic stem cell transplantation for treatment of patients with advanced Hodgkin's lymphoma: a report of 11 cases].
Zhou SY; Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou AP; Feng FY
Ai Zheng; 2002 Apr; 21(4):405-8. PubMed ID: 12452021
[TBL] [Abstract][Full Text] [Related]
33. The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma.
Yang DH; Min JJ; Jeong YY; Ahn JS; Kim YK; Cho SH; Chung IJ; Bom HS; Kim HJ; Lee JJ
Ann Hematol; 2009 May; 88(5):425-32. PubMed ID: 19002686
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic evaluation and prognostic value of interim hybrid PET/CT with (18)F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma.
Zhao J; Qiao W; Wang C; Wang T; Xing Y
Hematology; 2007 Oct; 12(5):423-30. PubMed ID: 17852456
[TBL] [Abstract][Full Text] [Related]
35. Pretransplantation [18-F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-Hodgkin lymphoma undergoing reduced-intensity conditioning followed by allogeneic stem cell transplantation.
Dodero A; Crocchiolo R; Patriarca F; Miceli R; Castagna L; Ciceri F; Bramanti S; Frungillo N; Milani R; Crippa F; Fallanca F; Englaro E; Corradini P
Cancer; 2010 Nov; 116(21):5001-11. PubMed ID: 20665491
[TBL] [Abstract][Full Text] [Related]
36. Role of high-dose therapy and initial response in survival of poor-risk patients with aggressive non-Hodgkin's lymphoma: a retrospective series on 126 patients from a single center.
Bouabdallah R; Coso D; Costello R; Bardou VJ; Blaise D; Xerri L; Sainty D; Maraninchi D; Gastaut JA
Bone Marrow Transplant; 2000 Jan; 25(1):35-40. PubMed ID: 10654012
[TBL] [Abstract][Full Text] [Related]
37. The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma.
Moskowitz CH; Nimer SD; Glassman JR; Portlock CS; Yahalom J; Straus DJ; O'Brien JP; Elkin N; Bertino JR; Zelenetz AD
Bone Marrow Transplant; 1999 Mar; 23(6):561-7. PubMed ID: 10217186
[TBL] [Abstract][Full Text] [Related]
38. Positron emission tomography using F-18 fluorodeoxyglucose pre- and post-autologous stem cell transplant in non-Hodgkin's lymphoma.
Johnston PB; Wiseman GA; Micallef IN
Bone Marrow Transplant; 2008 Jun; 41(11):919-25. PubMed ID: 18391991
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
[TBL] [Abstract][Full Text] [Related]
40. High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin's lymphomas: a single center experience on 18 patients.
Blay JY; Sebban C; Surbiguet C; Ouachée M; Philip I; Philip T; Biron P
Bone Marrow Transplant; 1998 Jan; 21(1):51-4. PubMed ID: 9486494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]